Swiss National Bank Sells 2,800 Shares of Silk Road Medical, Inc (NASDAQ:SILK)

Swiss National Bank lessened its position in shares of Silk Road Medical, Inc (NASDAQ:SILK) by 3.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 82,300 shares of the company’s stock after selling 2,800 shares during the period. Swiss National Bank owned approximately 0.21% of Silk Road Medical worth $3,220,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Keybank National Association OH increased its holdings in Silk Road Medical by 20.5% during the 1st quarter. Keybank National Association OH now owns 6,036 shares of the company’s stock worth $236,000 after acquiring an additional 1,027 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of Silk Road Medical by 4,900.9% in the 1st quarter. Tower Research Capital LLC TRC now owns 16,653 shares of the company’s stock worth $652,000 after buying an additional 16,320 shares during the last quarter. GW&K Investment Management LLC increased its holdings in shares of Silk Road Medical by 15.2% in the 1st quarter. GW&K Investment Management LLC now owns 170,093 shares of the company’s stock worth $6,656,000 after buying an additional 22,432 shares during the last quarter. California State Teachers Retirement System increased its holdings in shares of Silk Road Medical by 4.0% in the 1st quarter. California State Teachers Retirement System now owns 47,451 shares of the company’s stock worth $1,857,000 after buying an additional 1,806 shares during the last quarter. Finally, US Bancorp DE increased its holdings in shares of Silk Road Medical by 66.4% in the 1st quarter. US Bancorp DE now owns 2,290 shares of the company’s stock worth $90,000 after buying an additional 914 shares during the last quarter.

Insider Buying and Selling at Silk Road Medical

In other Silk Road Medical news, insider Andrew S. Davis sold 6,587 shares of the stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $22.13, for a total transaction of $145,770.31. Following the completion of the sale, the insider now owns 109,534 shares of the company’s stock, valued at approximately $2,423,987.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, CEO Erica J. Rogers sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, July 11th. The shares were sold at an average price of $31.56, for a total value of $31,560.00. Following the completion of the sale, the chief executive officer now directly owns 269,639 shares of the company’s stock, valued at approximately $8,509,806.84. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Andrew S. Davis sold 6,587 shares of the firm’s stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $22.13, for a total transaction of $145,770.31. Following the completion of the sale, the insider now directly owns 109,534 shares of the company’s stock, valued at $2,423,987.42. The disclosure for this sale can be found here. Insiders sold 10,195 shares of company stock valued at $242,534 in the last quarter. Company insiders own 6.70% of the company’s stock.

Silk Road Medical Trading Up 1.9 %

Shares of SILK opened at $19.69 on Monday. The stock has a market capitalization of $764.62 million, a P/E ratio of -13.96 and a beta of 1.16. The company has a quick ratio of 8.90, a current ratio of 9.69 and a debt-to-equity ratio of 0.48. The firm has a fifty day simple moving average of $23.72 and a two-hundred day simple moving average of $34.10. Silk Road Medical, Inc has a twelve month low of $19.26 and a twelve month high of $58.04.

Silk Road Medical (NASDAQ:SILK) last announced its quarterly earnings results on Tuesday, August 1st. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.04. The business had revenue of $45.30 million during the quarter, compared to analysts’ expectations of $43.32 million. Silk Road Medical had a negative net margin of 32.83% and a negative return on equity of 40.05%. On average, research analysts anticipate that Silk Road Medical, Inc will post -1.46 EPS for the current year.

Analyst Ratings Changes

SILK has been the topic of a number of research analyst reports. CL King initiated coverage on shares of Silk Road Medical in a report on Tuesday, May 23rd. They issued a “buy” rating and a $47.00 price target on the stock. Stifel Nicolaus decreased their price target on shares of Silk Road Medical from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Wednesday, August 2nd. Wolfe Research decreased their price target on shares of Silk Road Medical from $27.00 to $13.00 in a report on Tuesday, July 18th. B. Riley decreased their price target on shares of Silk Road Medical from $58.00 to $54.00 and set a “buy” rating on the stock in a report on Wednesday, August 2nd. Finally, Argus cut their price objective on shares of Silk Road Medical from $70.00 to $55.00 in a research note on Monday, May 22nd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $38.44.

Silk Road Medical Company Profile

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a specialty balloon for the TCAR procedure.